Please assess the completion status of the following clinical trial:

Trial Title: Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status class I-II.~* Age: 18 Years to 40 Years.~* Women scheduled for elective Cesarean section under spinal anesthesia.~* indications for CS other than fetal or maternal pathology.~Exclusion Criteria:~* Height \< 150 or \> 180 cm~* Body mass index (BMI) \>35 kg/m2~* Contraindication for central neuraxial block~* Refusal to undergo regional anesthesia~* Known allergy to any of the study drugs,~* Infection at the site of injection,~* Coagulopathy,~* Indication to general anesthesia~* Baseline bradycardia (heart rate \< 60/min), or any cardiovascular disease~* Patients taking β-adrenergic blockers or any drugs that may alter normal response to study drugs.~* Arrhythmia such as atrial fibrillation, supraventricular tachycardia, heart block greater than first degree, left bundle branch block,~* Hypertension (systolic blood pressure more than 140 mm Hg or diastolic blood pressure more than 90 mm Hg), unstable angina or cardiomyopathy,~* Associated medical problem with pregnancy (as hypertension, diabetes mellitus, hepatic impairment or renal impairment)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Hyoscine butylbromide (Type: ACTIVE_COMPARATOR): None
- Control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).